NKGen Biotech Collaborated with the Parkinson’s Foundation for Novel Natural Killer Cell Therapy to Treat Advanced Parkinson’s Disease
Shots:
- NKGen Biotech collaborated with Parkinson’s Foundation to advance NKGen’s clinical program by using novel autologous NK cell therapy (SNK01) for advanced PD. The treatment is expected to be available to the clinic in 2023
- NK cells are designed to remove alpha-synuclein proteins, reduce autoreactive T cell-generated inflammation, and remove damaged neurons. SNK01 is currently being studied in clinical trials for advanced refractory solid tumors as monothx. and in combination with other agents
- NKGen Biotech stated that non-genetically altered, enhanced, and expanded NK cells (SNK01) can offer a completely new therapeutic approach for PD which currently lacks effective disease-modifying therapies
Ref: NKGen Biotech | Image: Bayer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
